Acute Effect of Evolocumab on Lipoprotein(a) Level and Inflammation in Patients with Coronary Artery Disease.
Seung Woo ChoiJoan KimGyeong Won JangYoung-Shin LeeJin Sun ParkJung Myung LeeHyung Oh KimHyemoon ChungJong Shin WooWoo Shik KimWeon KimPublished in: Journal of cardiovascular development and disease (2022)
One-time PCSK9 inhibitor treatment may be effective in lowering Lp(a) levels in Korean patients in the short term.